Merck Signs an R&D Funding Deal with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

Shots: Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences to support development of sac-TMT, currently in 15 global P-III trials across multiple cancers, including breast, endometrial, and lung As per the deal, Blackstone will provide Merck $700M to help fund sac-TMT development through 2026. In return, Blackstone is eligible for low-to-mid…

ByDipanshu DixitNovember 5, 2025

VIEWPOINTS

Enhancing R&D Prowess in Oncology: Denis R. Beckford-Vera from Champions Oncology in Conversation with PharmaShots

Shots: The complexity of human physiology continues to challenge drug development, as conventional models often fail to provide critical insights, resulting in high attrition rates Champions Oncology bridges this gap through patient-derived xenograft and ex vivo platforms built from real tumors, integrated with radiolabeled compounds for deeper R&D insights Denis R. Beckford-Vera, Head of Radiopharmacology…

BySaurabh ChaubeyOctober 13, 2025

THOUGHTSPOT

Trends in Biopharma: The Upsurge in Multi-Omics Analysis

Last month, we explored four key trends shaping the biopharma industry in 2025. In this follow-up, we spotlight the evolving role of multi-omics analysis—a field rapidly transforming how diseases are understood, diagnosed, and treated. In 2024, the global multi-omics market was valued at $2.72 billion and is projected to reach $9.91 billion by 2033, growing…

BySaurabh ChaubeySeptember 10, 2025

TOP 20

Top 20 R&D Spending Biopharma Companies of 2025

Shots: Research and Development (R&D) serves as the driving force behind groundbreaking therapeutic innovations, laying the foundation for advancements that transform patient health and overall well-being The global Top 20 pharmaceutical leaders spent ~$180B in 2024, with Merck & Co. contributing the most with a whopping $17.93B, followed by Johnson & Johnson ($17.23B) and Roche…

ByPrince GiriAugust 21, 2025

VIEWPOINTS

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Shots: Mohamed Eid, VP of Clinical Development & Medical Affairs, Cardio-Renal-Metabolism & Respiratory Medicine, at Boehringer Ingelheim, in a stimulating conversation with PharmaShots sheds light on the recent approval of Jardiance for the treatment of adults with chronic kidney disease Jardiance’s EMPA Kidney P-III trial results demonstrated a 28% relative risk reduction vs placebo. Jardiance…

BySaurabh ChaubeyDecember 5, 2023

EXCLUSIVE

Insights from Coralie Gressier-Sayag on Avapritinib Efficacy Data Presented at EHA 2023

Shots: Coralie started by giving a brief introduction about Systemic Mastocytosis (SM), a rare disease. She told us that in Europe, approximately 40,000 people live with SM, with 80-90% living with Indolent SM and the rest with Advanced SM She then gave an overview of the P-II PATHFINDER study evaluating avapritinib. The study's 2-year follow-up…

BySenior EditorAugust 30, 2023

Merck Signs an R&D Funding Deal with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)

Enhancing R&D Prowess in Oncology: Denis R. Beckford-Vera from Champions Oncology in Conversation with PharmaShots

Trends in Biopharma: The Upsurge in Multi-Omics Analysis

Top 20 R&D Spending Biopharma Companies of 2025

Unlocking Approval: Mohamed Eid Dives into the Exciting Approval of Jardiance for Adult CKD Treatment in a Captivating Chat with PharmaShots

Insights from Coralie Gressier-Sayag on Avapritinib Efficacy Data Presented at EHA 2023

Contact US

FOLLOW US